Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole

European Journal of Clinical Pharmacology

Volumn 54, Issue 5, 1998, Pages 399-404

  Andersson, T ^a   Bredberg, E ^a   Lagerstrom P O ^a   Naesdal, J ^a   Wilson, I ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Diclofenac; Interaction; Naproxen; NSAID; Omeprazole; Piroxican

Indexed keywords

DICLOFENAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; DICLOFENAC; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; NAPROXEN; OMEPRAZOLE; PIROXICAM;

EID: 0031875428     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050482     Document Type: Article

References (39)

1. Paakari I (1994) Epidemiological and financial aspects of the use of non-steroidal anti-inflammatory analgesics. Pharmacol Toxicol 75 [Suppl. II]: 56-59
2. Huang J, Hunt RH (1996) A clinician's view of strategies for preventing NSAID-induced gastrointestinal ulcers. Inflammopharmacology 4: 17-30
3. Larkai EN, Smith JL, Lidsky MD, Graham DY (1987) Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 82: 1153-1158
4. McCarthy DM (1989) Nonsteroidal antiinflammatory drug-induced ulcers: management by traditional therapies. Gastroenterology 96: 662-674
5. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA (1991) Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 114: 257-363
6. García Rodríguez LA, Jick H (1994) Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343: 769-772
7. García Rodríguez LA, Walker AM, Pérez Gutthann S (1992) Nonsteroidal Antiinflammaory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. Epidemiology 3: 337-342
8. Graham DY (1996) Nonsteroidal anti-inflammatory drugs. Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 91: 2080-2086
9. Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM et al (1998) A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 338: 719-726
10. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, et al (1998) Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 338: 727-734
11. Lagerström PO, Persson BA, (1984) Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 309: 347-356
12. Twomey TM, Bartolucci SR, Hobbs DC (1980) Analysis of piroxicam in plasma by high-performance liquid chromatography. J Chromatogr 183: 104-108
13. Lichtenberger LM, Ulloa C, Romero JJ, Vanous AL, Illich PA, Dial EJ (1996) Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: Combination therapy with antisecretory agents in rats. Gastroenterology 111: 990-995
14. Guarner F (1996) Prescribing nonsteroidal anti-inflammatory drugs together with antisecretory agents is safe but may be useless. Gastroenterology 111: 1145-1147
15. Brooks PM, Day RO (1991) Drug therapy (editorial): nonsteroidal anti-inflammatory drug-differences and similarities. N Engl J Med 324: 1716-1725
16. Lanzon-Miller S, Pounder RE, Hamilton MR, Ball S, Chronos NA, et al. (1987) Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1: 239-251
17. Poli, A. Moreno RA, Riberio W, Dias HB, Moreno JR H, Muscara MN, DeNucci G (1996) Influence of gastric acid secretion blockade and food intake on the bioavailability of a potassium diclol'enac suspension in healthy male volunteers. Int J Clin Pharmacol Ther 34: 76-79
18. Andersson T (1991) Pharmacokinetics of omepra/ole in man: with special reference to single and repeated adminstration, drug interactions and polymorphic metablolism. Thesis. University of Göteborg, Sweden
19. Ekenved G, Elofsson R, Sölvell L. (1975) Bioavailabilily studies on a buffered acetylsalicylic acid preparation. Acta Pharmacologica Suecia 12: 323-332
20. Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12: 415-416
21. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, et al (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36: 521-530
22. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, et al (1993) Oxidative metabolism of omepra/ole in human liver microsomes: congregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 266: 52-59
23. Andersson T, Miners JO, Veronese ME, Birkett DJ (1994) Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 37: 597-604
24. Leemann T, Transon C, Dayer P (1993) Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenace 4′-hydroxylation in human liver. Lite Sci 52: 29-34
25. Newlands AJ, Smith DA, Jones BC, Hawksworth GM, (1992) Metaholism of non-steroidal anti-inflammatory drugs by cytochrome P450 2C. Br J Clin Pliarmacol 34: 152P, (abstract)
26. Leemann TD, Transon C, Bonnabry P, Dayer P (1993) A major role for cytoclirome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res 19: 189-195
27. Doecke CJ, Veronese ME, Pond SM, et al (1991) Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 31: 125-130
28. Tassaneeyakul W, Veronese ME, Birkett D.I. et al. (1992) Coregulation of phenytoin and tolbutamide metabolism in humans. Br J Clin Pharmacol 34: 494-498
29. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA (1990) Tolbutamide and mephenytoin hydroxylation by human cytoclirome P450s in the CYP3C subfamily. J Phannacol Exp Ther 252: 442-447
30. Kaminsky LS, de Morais SM, Faletto MB, Dunbar DA, Goldstein JA (1994) Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pliarmacol 43: 234-239
31. Gugler R, Jensen JO (1985) Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 89: 1235-1241
32. Prichard PJ, Walt RP, Kitchingman GK, et al (1987) Oral phenytoin pharmacokinetics during omepra/ole therapy. Br J Clin Pharmacol 24: 543-545
33. Bachmann KA, Sullivan TJ, Jauregui L, Reese JH, Miller K, Levine L, (1993) Absence of inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. Br J Clin Phannacol 36: 380-382
34. Andersson T, Lagerström PO, Unge P (1990) A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit 12: 329-333
35. Toon S, Holt BL, Mullins FGP, Khan A (1995) Effects of cimetidine, ranitidine and omeprazole on tolbutamide pharmacokinetics. J Pharm Pharmacol 47: 85-88
36. Hall SD, Hamman MA, Rettie AE, Wienkers LC, Trager WF, et al (1994) Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsonies. Drug Metab Dispos 22: 975-978
37. Hashimoto Y, Otsuki Y, Odani A, Takano M, Hattori H, et al (1996) Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Biol Pharm Bull 19: 1103-1105
38. Sutfin T, Balmer K, Boström H, Eriksson S, Höglund P, Paulsen O (1989) Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 11: 176-184
39. Unge P, Svedberg LE, Nordgren A. et al (1992) A study of the interaction of omepra/ole and warfarin in anticoagulated patients. Br J Clin Pharmacol 34: 509-512